Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J 
Welcome,         Profile    Billing    Logout  
 4 Diseases   7 Trials   7 Trials   767 News 


12345678910»
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Retrospective data, Journal:  Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis. (Pubmed Central) -  Jun 24, 2025   
    P3
    In addition, >56% of patients who transitioned from PP3M to PP6M or continued PP6M treatment had sustained combined (symptomatic and functional) remission at the OLE endpoint. These findings support the long-term efficacy of PP3M and PP6M, highlighting the potential benefits of transitioning to longer acting antipsychotic formulations in achieving and sustaining both symptomatic stability and functional improvement in adults with schizophrenia.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Journal:  One-Year Evaluation of Paliperidone Palmitate 6-Monthly: Satisfaction and Perceived Effectiveness Among Patients, Relatives, and Clinicians. (Pubmed Central) -  Jun 3, 2025   
    Patients, their carers and relatives as well as mental health professionals reported a high satisfaction rate with PP6M, and equally good or even better perceived effectiveness compared to PP1M, PP3M or other oral or LAIs antipsychotics in the majority of cases. Improved patient experience with PP6M could improve treatment continuity and reduce hospitalization rates.
  • ||||||||||  risperidone / Generic mfg., Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Journal, Real-world evidence:  An analysis of the clinical application of paliperidone palmitate injection based on real-world. (Pubmed Central) -  Apr 10, 2025   
    Patients with initial episodes with and adhering to PP injection were at lower risk of relapse. Thus, the patients' adherence and the education about PP injections should be improved.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Real-World Adherence, Healthcare Resource Utilization, And Costs Among Patients With Schizophrenia Utilizing Once-Monthly, Once-Every-Three-Months, And Once-Every-Six-Months Paliperidone Palmitate in the United States () -  Mar 24, 2025 - Abstract #ISPOR2025ISPOR_1556;    
    OBJECTIVES: Once-every-6-months paliperidone palmitate (PP6M) is the longest dosing interval long-acting injectable (LAI) antipsychotic, followed by once-every-three-months paliperidone palmitate (PP3M). In this real-world descriptive study, patients with schizophrenia using PP3M or PP6M were more adherent, incurred lower medical costs, and a lower proportion had a schizophrenia-related inpatient admission relative to patients using PP1M, suggesting LAIs with longer dosing intervals may improve clinical outcomes and decrease medical costs.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Journal:  Comparing two transitioning strategies to paliperidone palmitate once-every-6-months. (Pubmed Central) -  Feb 19, 2025   
    P3
    Adults with schizophrenia who transitioned to PP6M from either PP1M or PP3M experienced similarly low relapse rates. Additionally, symptom and functionality scores supported the primary analysis and, along with TEAE incidences, were comparable between transition groups.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal:  In brief: Erzofri - another once-monthly paliperidone formulation. (Pubmed Central) -  Oct 9, 2024   
    PP3M may significantly reduce hospitalisation duration, emergency room visits, and health-care costs in patients with schizophrenia. No abstract available
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Review, Journal:  Combination of Two Long-Acting Antipsychotics in Schizophrenia Spectrum Disorders: A Systematic Review. (Pubmed Central) -  May 25, 2024   
    Policy initiatives that remove barriers to primary adherence or fulfillment may help improve patients' clinical outcomes. Our review highlights that the treatment regimen with two concurrent LAI APs is already widely used in clinical practice and is recognized as providing a promising, effective, and relatively safe therapeutic strategy for treating the schizophrenia spectrum disorders.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Trial completion:  CASPAR: A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (clinicaltrials.gov) -  May 22, 2024   
    P4,  N=93, Completed, 
    Our review highlights that the treatment regimen with two concurrent LAI APs is already widely used in clinical practice and is recognized as providing a promising, effective, and relatively safe therapeutic strategy for treating the schizophrenia spectrum disorders. Active, not recruiting --> Completed
  • ||||||||||  Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Review, Journal:  Switching from paliperidone palmitate 3-monthly long-acting injection to oral aripiprazole in a pregnant woman with schizophrenia: a case report and short review. (Pubmed Central) -  Apr 27, 2024   
    No obstetrical or fetal complications were reported. As the research in this field is very demanding, it would be precipitous to derive final conclusions from the current case report, but we hope to build a growing number of data that would allow us to make more appropriate and safe therapeutic choices in such a vulnerable phase as the peripartum.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Hypercalcemia related to Paliperidone in ESRD patient () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_682;    
    58 year-old male with diabetes,schizo affective disorder,ESRD on hemodialysis had hypercalcemia on monthly dialysis labs.Being on dialysis for a year,his mineral bone disease was well controlled without requiring any phosphate binders or calcimimetics.Home meds were insulin,ability and benztropine.Due to uncontrolled schizoaffective disorder,monthly paliperidone injection was started which helped his symptoms remarkably.Within few months of starting paliperidone,we noted a strange association of hypercalcemia,which couldn't be explained otherwise.Calcium stayed above 10.5 mg/dl the week or following week of getting injection paliperidone while it normalized 3-4 weeks later.PTH levels were between 300-450 while his phosphorus stayed in range 3.5-4.5.Hypercalcemia workup for malignancy,paraproteinemia,Vit D intoxication,granulomatous disorders were negative.He wasn't on calcium-based binders or calcium supplement nor taking common hypercalcemia causing drugs like thiazide or lithium.He was not limited by mobility.His prolactin was elevated at 192. Hypercalcemia workup should include atypical antipsychotics drugs in schizoaffective ESRD patients.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal:  Mining oomycete proteomes for phosphatome leads to the identification of specific expanded phosphatases in oomycetes. (Pubmed Central) -  Mar 15, 2024   
    To delve further into its function, we generated knockout mutants of PPM1 and validated its essential roles in mycelial growth, sporangia and oospore production, as well as infectious stages. To the best of our knowledge, this study provides the first comprehensive inventory of phosphatases in oomycetes and identifies an important phosphatase within the expanded serine/threonine phosphatase group in oomycetes.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Review, Journal:  Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults. (Pubmed Central) -  Mar 12, 2024   
    PP6M allows a longer dosing interval than any other LAI antipsychotics, potentially reducing nonadherence and disease relapses. In future, an increase in the prescription rates of PP6M is expected and real-world efficacy and tolerability studies will be conducted.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal, Adverse events:  Oral and long-acting injectable antipsychotic discontinuation and relationship to side effects in people with first episode psychosis: a longitudinal analysis of electronic health record data. (Pubmed Central) -  Dec 18, 2023   
    Among first prescribed antipsychotic medications, discontinuation occurred earlier with haloperidol [hazard ratio (HR)?=?2.78, 95% CI?=?1.69-4.60] and quetiapine (HR?=?1.43, 95% CI?=?1.16-1.80) than with olanzapine...Among antipsychotics prescribed at any point during treatment, lurasidone (HR?=?1.40, 95% CI?=?1.10-1.78) and aripiprazole (HR?=?1.09, 95% CI?=?1.01-1.19) were associated with earlier discontinuation than olanzapine...Later treatment discontinuation associated with clozapine and PP1M could be related to the relative efficacy of these treatments. These findings merit consideration when selecting antipsychotic therapy for people with FEP.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Clinical, Review, Journal:  Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review. (Pubmed Central) -  Sep 25, 2023   
    Paliperidone palmitate once-monthly injection (27/46) and risperidone LAI (14/46) were the most frequently investigated LAIs...Better adherence and lower relapse were observed in patients receiving LAIs from published evidence. Future research is warranted to better understand the comprehensive performance of LAI in specific population or context.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Journal, HEOR:  Cost-utility analysis of using paliperidone palmitate in schizophrenia in China. (Pubmed Central) -  Aug 21, 2023   
    The probability sensitivity analysis (PSA) revealed that when the WTP thresholds were $12,756.55/QALY, the probability of PP1M and PP3M being cost-effective was 59.2% and 66.0%, respectively. From the Chinese healthcare system perspective, PP3M and PP1M are both more cost-effective compared to ER, and PP3M has notable cost-utility advantages over PP1M.